News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Deals
Epocrates Inc. Cancels IPO
December 16, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Epocrates Inc., a San Mateo, Calif.-based provider of clinical information and support tools to healthcare professionals, has withdrawn plans for a $75 million IPO. It had planned to trade on the Nasdaq, with Citi serving as lead underwriter.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
ALS
Lilly Deepens ALS Pipeline With $415M Alchemab Licensing Deal
May 6, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Kronos Accepts $35M Concentra Buyout as Walls Close In
May 2, 2025
·
2 min read
·
Annalee Armstrong
Earnings
Tariffs Keep Biogen Execs Busy in Q1 but Impacts Expected To Be Minimal
May 1, 2025
·
3 min read
·
Annalee Armstrong
Deals
Novartis Strikes on M&A, Leading a Line of Big Pharmas With Cash to Spend
April 30, 2025
·
5 min read
·
Annalee Armstrong
